Hemic and Lymphatic Diseases

593 trials 238 recruiting

Filter these 593 trials by phase, country and sponsor.

Open in Search →

Phase 2, Open-Label Study Evaluating Axi-Cel as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible … Ended

2024-513659-34-00 Relapsed/Refractory aggressive B-NHL 9 2021-02-12
KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERA… Ended

2024-513252-15-00 IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL 4 2021-01-28
Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia (CZAR-1) Ended

2024-511929-60-00 Waldenström’s Macroglobulinemia 4 2021-01-28
A Phase 1b/2 Study of the Combination of Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Ended

2023-503439-16-00 Multiple Myeloma 9 2020-12-29
Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or without Selinexor in Patients with Diffuse Large B-Cell Lymphoma Ended

2024-513616-95-00 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR D 10 2020-12-22
Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk… Ended

2023-507153-16-00 Higher-Risk Myelodysplastic Syndrome 5 2020-11-18
Loc-R01: Randomized Phase IB/II Study of escalating doses of Lenalidomide and Ibrutinib in association with R-MPV as a targeted induction tr… Ended

2024-515331-30-00 Primary Central Nervous System Lymphoma (PCNSL) 7 2020-10-30
A study of mitapivat in sickle cell disease Ended

2024-515569-32-00 Sickle cell disease 4 2020-09-24
POLAR BEAR Ended

2022-502887-19-00 Diffuse Large B-Cell Lymphoma 5 2020-08-18
Fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B Ended

2024-512501-76-00 Hemophilia 10 2020-07-28
Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA) Ended

2024-512731-74-00 multiple myeloma 4 2020-07-03
A first-in-human clinical study to assess feasibility, safety and antitumor activity of genetically modified T-cells in multiple myeloma Ended

2024-512643-23-00 Multiple myeloma 7 2020-06-22
A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-s… Ended

2024-514592-17-00 chronic myeloid leukemia 4 2020-06-16
A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES). Ended

2023-510455-28-00 Hypereosinophilic Syndrome (HES) 5 2020-06-10
Phase III study of GSK2857916, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in participants with relapsed… Ended

2023-510537-28-00 Multiple Myeloma 5 2020-05-15
Longterm Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product Ended

2024-513904-33-00 Cerebral Adrenoleukodystrophy (CALD) 5 2020-03-11
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extr… Ended

2024-514963-24-00 Multiple Myeloma patients presenting with extramedullar 4 2020-02-04
A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemop… Ended

2022-502844-11-00 severe to moderately severe hemophilia B (FIX:C ≤ 2%) 5 2020-01-29
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previo… Ended

2024-511747-25-00 B-cell non-Hodgkin lymphoma (NHL) 4 2019-12-23
A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in unfit… Ended

2023-503829-18-00 Acute myeloid leukemia 4 2019-12-05
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (COUP-1) Ended

2022-500674-34-00 Marginal Zone Lymphoma 4 2019-11-04
Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia Ended

2022-500584-12-00 Waldenström’s Macroglobulinemia 4 2019-09-11
Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended

2024-515375-35-00 Untreated patients with higher risk MDS and oligoblasti 4 2019-08-26